Portal de investigação
Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Bousquet, J
- Schröder-Bernhardi, D
- Bachert, C
- Canonica, GW
- Cardona, V
- Costa, EM
- Czarlewski, W
- Devillier, P
- Klimek, L
- Kuna, P
- Lourenco, O
- Mullol, J
- Pfaar, O
- Pham Thi, N
- Samolinski, B
- Saueressig, J
- Scadding, GK
- Stroh, AK
- Scheire, S
- Van Ganse, E
- Zuberbier, T
Unidades de investigação
Abstract
Background The practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis differ depending on practices and health systems. To understand these differences and their implications, the rhinitis market was studied in some of the EU countries. Methods We conducted a pharmaco-epidemiological database analysis to assess the medications that were being prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA platforms for prescribed medicines (MIDAS((R)-)Meaningful Integration of Data, Analytics and Services) and for OTC medicines (OTC International Market Tracking-OTCims). We selected the five most important markets in the EU (France, Germany, Italy, Poland and Spain). Results Intranasal decongestants were excluded from the analyses because they are rarely prescribed for allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the three others. However, medication use differs largely. For 2018, in SU, intranasal corticosteroid is the first treatment in Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%), whereas the Italian market is dominated by systemic antihistamines (41.4%) followed by intranasal corticosteroids (30.1%). Results of other years were similar. Discussion There are major differences between countries in terms of rhinoconjunctivitis medication usage.
© 2021 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Dados da publicação
- ISSN/ISSNe:
- 0954-7894, 1365-2222
- Tipo:
- Article
- Páginas:
- 1033-1045
- DOI:
- 10.1111/cea.13884
- Link para outro recurso:
- www.scopus.com
Clinical and Experimental Allergy Wiley-Blackwell Publishing Ltd
Citações Recebidas na Web of Science: 13
Citações Recebidas na Scopus: 11
Documentos
- Não há documentos
Filiações
Keywords
- allergic rhinitis; costs; medications; MIDAS; units
Proyectos asociados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Citar a publicação
Bousquet J,Schröder D,Bachert C,Canonica GW,Cardona V,Costa EM,Czarlewski W,Devillier P,Fonseca J,Klimek L,Kuna P,Lourenco O,Mullol J,Pfaar O,Pham N,Samolinski B,Saueressig J,Scadding GK,Stroh AK,Scheire S,Van E,Zuberbier T. Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. Clin. Exp. Allergy. 2021. 51. (8):p. 1033-1045. IF:5,401. (2).
